A focus on glucose-mediated drug delivery to the central nervous system

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 4, 2012, Pages 301-312

  Serrano, I D ^a   Ribeiro, M M B ^a   Castanho, M A R B ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Blood brain barrier; Central nervous system; Drug delivery; Glucose derivatives; Glucose transporter; Glycosylation

Indexed keywords

7 CHLOROKYNURENIC ACID; ALPHA METHYL MANNOSIDE; ANALGESIC AGENT; DOPAMINE; ENKEPHALIN DERIVATIVE; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; IBUPROFEN; INDINAVIR; INDOMETACIN; KETOPROFEN; LEUCINE ENKEPHALIN DERIVATIVE; LOPERAMIDE; MORPHINE; NELFINAVIR; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; RESERPINE; SAQUINAVIR;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; EPILEPSY; GLUCOSE TRANSPORT; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOCICEPTIVE PAIN; NONHUMAN; PAIN; PARKINSON DISEASE; PLASMA HALF LIFE; REVIEW;

ANIMALS; BRAIN; BRAIN DISEASES; DRUG DELIVERY SYSTEMS; GLUCOSE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLYCOSYLATION; HUMANS;

EID: 84858314405     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712799829302     Document Type: Review

References (107)

1. Pardridge, W. M., Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov Today 2002, 7 (1), 5-7.
2. Kissin, I., The development of new analgesics over the past 50 years: a lack of real breakthrough drugs. Anesth Analg 2010, 110 (3), 780-9.
3. Begley, D. J., Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 2004, 104 (1), 29-45.
4. Pardridge, W. M., Drug targeting to the brain. Pharm Res 2007, 24 (9), 1733-44.
5. Begley, D. J., ABC transporters and the blood-brain barrier. Curr Pharm Des 2004, 10 (12), 1295-312.
6. Greig, N. H.; Fredericks, W. R.; Holloway, H. W.; Soncrant, T. T.; Rapoport, S. I., Delivery of human interferon-alpha to brain by transient osmotic blood-brain barrier modification in the rat. J Pharmacol Exp Ther 1988, 245 (2), 581-6.
7. LaManna, J. C.; Harik, S. I., Regional comparisons of brain glucose influx. Brain Res 1985, 326 (2), 299-305.
8. Diamond, J. M.; Wright, E. M., Molecular forces governing nonelectrolyte permeation through cell membranes. Proc R Soc Lond B Biol Sci 1969, 171 (28), 273-316.
9. Fischer, H.; Gottschlich, R.; Seelig, A., Blood-brain barrier permeation: molecular parameters governing passive diffusion. J Membr Biol 1998, 165 (3), 201-11.
10. Egleton, R. D.; Davis, T. P., Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx 2005, 2 (1), 44-53.
11. Janecka, A.; Perlikowska, R.; Gach, K.; Wyrebska, A.; Fichna, J., Development of opioid peptide analogs for pain relief. Curr Pharm Des 2010, 16 (9), 1126-35.
12. Anderson, B. D., Prodrugs for improved CNS delivery. Advanced Drug Delivery Reviews 1996, 19 (2), 171-202.
13. Guo, X.; Geng, M.; Du, G., Glucose transporter 1, distribution in the brain and in neural disorders: its relationship with transport of neuroactive drugs through the blood-brain barrier. Biochem Genet 2005, 43 (3-4), 175-87.
14. Simpson, I. A.; Carruthers, A.; Vannucci, S. J., Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J Cereb Blood Flow Metab 2007, 27 (11), 1766-91.
15. Brown, G. K., Glucose transporters: structure, function and consequences of deficiency. J Inherit Metab Dis 2000, 23 (3), 237-46.
16. McEwen, B. S.; Reagan, L. P., Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol 2004, 490 (1-3), 13-24.
17. Qutub, A. A.; Hunt, C. A., Glucose transport to the brain: a systems model. Brain Res Brain Res Rev 2005, 49 (3), 595-617.
18. McAllister, M. S.; Krizanac-Bengez, L.; Macchia, F.; Naftalin, R. J.; Pedley, K. C.; Mayberg, M. R.; Marroni, M.; Leaman, S.; Stanness, K. A.; Janigro, D., Mechanisms of glucose transport at the blood-brain barrier: an in vitro study. Brain Res 2001, 904 (1), 20-30.
19. Gruetter, R.; Novotny, E. J.; Boulware, S. D.; Rothman, D. L.; Mason, G. F.; Shulman, G. I.; Shulman, R. G.; Tamborlane, W. V., Direct measurement of brain glucose concentrations in humans by 13C NMR spectroscopy. Proc Natl Acad Sci U S A 1992, 89 (3), 1109-12.
20. Cremer, J. E., Substrate utilization and brain development. J Cereb Blood Flow Metab 1982, 2 (4), 394-407.
21. De Vivo, D. C.; Trifiletti, R. R.; Jacobson, R. I.; Ronen, G. M.; Behmand, R. A.; Harik, S. I., Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med 1991, 325 (10), 703-9.
22. Klepper, J.; Leiendecker, B., GLUT1 deficiency syndrome-2007 update. Dev Med Child Neurol 2007, 49 (9), 707-16.
23. Klepper, J.; Voit, T., Facilitated glucose transporter protein type 1 (GLUT1) deficiency syndrome: impaired glucose transport into brain-a review. Eur J Pediatr 2002, 161 (6), 295-304.
24. Fukumoto, H.; Seino, S.; Imura, H.; Seino, Y.; Bell, G. I., Characterization and expression of human HepG2/erythrocyte glucose-transporter gene. Diabetes 1988, 37 (5), 657-61.
25. Birnbaum, M. J.; Haspel, H. C.; Rosen, O. M., Cloning and characterization of a cDNA encoding the rat brain glucosetransporter protein. Proc Natl Acad Sci U S A 1986, 83 (16), 5784-8.
26. Cornford, E. M.; Hyman, S.; Pardridge, W. M., An electron microscopic immunogold analysis of developmental up-regulation of the blood-brain barrier GLUT1 glucose transporter. J Cereb Blood Flow Metab 1993, 13 (5), 841-54.
27. Farrell, C. L.; Pardridge, W. M., Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: an electron microscopic immunogold study. Proc Natl Acad Sci U S A 1991, 88 (13), 5779-83.
28. Simpson, I. A.; Vannucci, S. J.; DeJoseph, M. R.; Hawkins, R. A., Glucose transporter asymmetries in the bovine blood-brain barrier. J Biol Chem 2001, 276 (16), 12725-9.
29. Hawkins, R. A.; Peterson, D. R.; Vina, J. R., The complementary membranes forming the blood-brain barrier. IUBMB Life 2002, 54 (3), 101-7.
30. Mueckler, M.; Caruso, C.; Baldwin, S. A.; Panico, M.; Blench, I.; Morris, H. R.; Allard, W. J.; Lienhard, G. E.; Lodish, H. F., Sequence and structure of a human glucose transporter. Science 1985, 229 (4717), 941-5.
31. Mueckler, M.; Makepeace, C., Transmembrane segment 12 of the Glut1 glucose transporter is an outer helix and is not directly involved in the transport mechanism. J Biol Chem 2006, 281 (48), 36993-8.
32. Salas-Burgos, A.; Iserovich, P.; Zuniga, F.; Vera, J. C.; Fischbarg, J., Predicting the three-dimensional structure of the human facilitative glucose transporter glut1 by a novel evolutionary homology strategy: insights on the molecular mechanism of substrate migration, and binding sites for glucose and inhibitory molecules. Biophys J 2004, 87 (5), 2990-9.
33. Mueckler, M.; Makepeace, C., Transmembrane segment 6 of the Glut1 glucose transporter is an outer helix and contains amino acid side chains essential for transport activity. J Biol Chem 2008, 283 (17), 11550-5.
34. Fernandez, C.; Nieto, O.; Rivas, E.; Montenegro, G.; Fontenla, J. A.; Fernandez-Mayoralas, A., Synthesis and biological studies of glycosyl dopamine derivatives as potential antiparkinsonian agents. Carbohydr Res 2000, 327 (4), 353-65.
35. Boado, R. J.; Wang, L.; Pardridge, W. M., Enhanced expression of the blood-brain barrier GLUT1 glucose transporter gene by brainderived factors. Brain Res Mol Brain Res 1994, 22 (1-4), 259-67.
36. Hussar, P.; Tserentsoodol, N.; Koyama, H.; Yokoo-Sugawara, M.; Matsuzaki, T.; Takami, S.; Takata, K., The glucose transporter GLUT1 and the tight junction protein occludin in nasal olfactory mucosa. Chem Senses 2002, 27 (1), 7-11.
37. Lippoldt, A.; Kniesel, U.; Liebner, S.; Kalbacher, H.; Kirsch, T.; Wolburg, H.; Haller, H., Structural alterations of tight junctions are associated with loss of polarity in stroke-prone spontaneously hypertensive rat blood-brain barrier endothelial cells. Brain Res 2000, 885 (2), 251-61.
38. Abbott, N. J., Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 2002, 200 (6), 629-38.
39. Maher, F.; Vannucci, S. J.; Simpson, I. A., Glucose transporter proteins in brain. Faseb J 1994, 8 (13), 1003-11.
40. Ximenes da Silva, A.; Lavialle, F.; Gendrot, G.; Guesnet, P.; Alessandri, J. M.; Lavialle, M., Glucose transport and utilization are altered in the brain of rats deficient in n-3 polyunsaturated fatty acids. J Neurochem 2002, 81 (6), 1328-37.
41. Elfeber, K.; Kohler, A.; Lutzenburg, M.; Osswald, C.; Galla, H. J.; Witte, O. W.; Koepsell, H., Localization of the Na+-D-glucose cotransporter SGLT1 in the blood-brain barrier. Histochem Cell Biol 2004, 121 (3), 201-7.
42. Vannucci, S. J.; Simpson, I. A., Developmental switch in brain nutrient transporter expression in the rat. Am J Physiol Endocrinol Metab 2003, 285 (5), E1127-34.
43. Maher, F.; Vannucci, S.; Takeda, J.; Simpson, I. A., Expression of mouse-GLUT3 and human-GLUT3 glucose transporter proteins in brain. Biochem Biophys Res Commun 1992, 182 (2), 703-11.
44. Nagamatsu, S.; Kornhauser, J. M.; Burant, C. F.; Seino, S.; Mayo, K. E.; Bell, G. I., Glucose transporter expression in brain. cDNA sequence of mouse GLUT3, the brain facilitative glucose transporter isoform, and identification of sites of expression by in situ hybridization. J Biol Chem 1992, 267 (1), 467-72.
45. Vannucci, S. J., Developmental expression of GLUT1 and GLUT3 glucose transporters in rat brain. J Neurochem 1994, 62 (1), 240-6.
46. Vannucci, S. J.; Maher, F.; Simpson, I. A., Glucose transporter proteins in brain: delivery of glucose to neurons and glia. Glia 1997, 21 (1), 2-21.
47. Vannucci, S. J.; Clark, R. R.; Koehler-Stec, E.; Li, K.; Smith, C. B.; Davies, P.; Maher, F.; Simpson, I. A., Glucose transporter expression in brain: relationship to cerebral glucose utilization. Dev Neurosci 1998, 20 (4-5), 369-79.
48. Mooradian, A. D.; Chung, H. C.; Shah, G. N., GLUT-1 expression in the cerebra of patients with Alzheimer's disease. Neurobiol Aging 1997, 18 (5), 469-74.
49. Simpson, I. A.; Chundu, K. R.; Davies-Hill, T.; Honer, W. G.; Davies, P., Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol 1994, 35 (5), 546-51.
50. Duelli, R.; Staudt, R.; Duembgen, L.; Kuschinsky, W., Increase in glucose transporter densities of Glut3 and decrease of glucose utilization in rat brain after one week of hypoglycemia. Brain Res 1999, 831 (1-2), 254-62.
51. Powell, M. F.; Stewart, T.; Otvos, L., Jr.; Urge, L.; Gaeta, F. C.; Sette, A.; Arrhenius, T.; Thomson, D.; Soda, K.; Colon, S. M., Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharm Res 1993, 10 (9), 1268-73.
52. Fisher, J. F.; Harrison, A. W.; Bundy, G. L.; Wilkinson, K. F.; Rush, B. D.; Ruwart, M. J., Peptide to glycopeptide: glycosylated oligopeptide renin inhibitors with attenuated in vivo clearance properties. J Med Chem 1991, 34 (10), 3140-3.
53. Egleton, R. D.; Mitchell, S. A.; Huber, J. D.; Palian, M. M.; Polt, R.; Davis, T. P., Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation. J Pharmacol Exp Ther 2001, 299 (3), 967-72.
54. Lis, H.; Sharon, N., Protein glycosylation. Structural and functional aspects. Eur J Biochem 1993, 218 (1), 1-27.
55. Herzner, H.; Reipen, T.; Schultz, M.; Kunz, H., Synthesis of glycopeptides containing carbohydrate and Peptide recognition motifs. Chem Rev 2000, 100 (12), 4495-538.
56. Seitz, O., Glycopeptide synthesis and the effects of glycosylation on protein structure and activity. Chembiochem 2000, 1 (4), 214-46.
57. Sinclair, A. M.; Elliott, S., Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci 2005, 94 (8), 1626-35.
58. Sewald, N.; Jakubke, H. D., Peptides: Chemistry and Biology. Wiley-VCH: Weinheim, 2009.
59. Polt, R.; Dhanasekaran, M.; Keyari, C. M., Glycosylated neuropeptides: a new vista for neuropsychopharmacology? Med Res Rev 2005, 25 (5), 557-85.
60. Bilsky, E. J.; Egleton, R. D.; Mitchell, S. A.; Palian, M. M.; Davis, P.; Huber, J. D.; Jones, H.; Yamamura, H. I.; Janders, J.; Davis, T. P.; Porreca, F.; Hruby, V. J.; Polt, R., Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability. J Med Chem 2000, 43 (13), 2586-90.
61. Gaggelli, E.; Kozlowski, H.; Valensin, D.; Valensin, G., Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem Rev 2006, 106 (6), 1995-2044.
62. Hardy, J.; Selkoe, D. J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297 (5580), 353-6.
63. Selkoe, D. J., Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 2001, 3 (1), 75-80.
64. Atwood, C. S.; Moir, R. D.; Huang, X.; Scarpa, R. C.; Bacarra, N. M.; Romano, D. M.; Hartshorn, M. A.; Tanzi, R. E.; Bush, A. I., Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 1998, 273 (21), 12817-26.
65. Huang, X.; Atwood, C. S.; Hartshorn, M. A.; Multhaup, G.; Goldstein, L. E.; Scarpa, R. C.; Cuajungco, M. P.; Gray, D. N.; Lim, J.; Moir, R. D.; Tanzi, R. E.; Bush, A. I., The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999, 38 (24), 7609-16.
66. Atwood, C. S.; Obrenovich, M. E.; Liu, T.; Chan, H.; Perry, G.; Smith, M. A.; Martins, R. N., Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. Brain Res Brain Res Rev 2003, 43 (1), 1-16.
67. Storr, T.; Scott, L. E.; Bowen, M. L.; Green, D. E.; Thompson, K. H.; Schugar, H. J.; Orvig, C., Glycosylated tetrahydrosalens as multifunctional molecules for Alzheimer's therapy. Dalton Trans 2009, (16), 3034-43.
68. Vlad, S. C.; Miller, D. R.; Kowall, N. W.; Felson, D. T., Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008, 70 (19), 1672-7.
69. Chen, Q.; Gong, T.; Liu, J.; Wang, X.; Fu, H.; Zhang, Z., Synthesis, in vitro and in vivo characterization of glycosyl derivatives of ibuprofen as novel prodrugs for brain drug delivery. J Drug Target 2009, 17 (4), 318-28.
70. Di Stefano, A.; Mosciatti, B.; Cingolani, G. M.; Giorgioni, G.; Ricciutelli, M.; Cacciatore, I.; Sozio, P.; Claudi, F., Dimeric Ldopa derivatives as potential prodrugs. Bioorg Med Chem Lett 2001, 11 (8), 1085-8.
71. Bonina, F.; Puglia, C.; Rimoli, M. G.; Melisi, D.; Boatto, G.; Nieddu, M.; Calignano, A.; La Rana, G.; De Caprariis, P., Glycosyl derivatives of dopamine and L-dopa as anti-Parkinson prodrugs: synthesis, pharmacological activity and in vitro stability studies. J Drug Target 2003, 11 (1), 25-36.
72. Fernandez, C.; Nieto, O.; Fontenla, J. A.; Rivas, E.; de Ceballos, M. L.; Fernandez-Mayoralas, A., Synthesis of glycosyl derivatives as dopamine prodrugs: interaction with glucose carrier GLUT-1. Org Biomol Chem 2003, 1 (5), 767-71.
73. Garcia-Alvarez, I.; Garrido, L.; Fernandez-Mayoralas, A., Studies on the uptake of glucose derivatives by red blood cells. ChemMedChem 2007, 2 (4), 496-504.
74. Yamazaki, M.; Mori, H.; Araki, K.; Mori, K. J.; Mishina, M., Cloning, expression and modulation of a mouse NMDA receptor subunit. FEBS Lett 1992, 300 (1), 39-45.
75. Battaglia, G.; La Russa, M.; Bruno, V.; Arenare, L.; Ippolito, R.; Copani, A.; Bonina, F.; Nicoletti, F., Systemically administered Dglucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents. Brain Res 2000, 860 (1-2), 149-56.
76. Choi, D. W., Excitotoxic cell death. J Neurobiol 1992, 23 (9), 1261-76.
77. Gronlund, K. M.; Gerhart, D. Z.; Leino, R. L.; McCall, A. L.; Drewes, L. R., Chronic seizures increase glucose transporter abundance in rat brain. J Neuropathol Exp Neurol 1996, 55 (7), 832-40.
78. Cornford, E. M.; Nguyen, E. V.; Landaw, E. M., Acute upregulation of blood-brain barrier glucose transporter activity in seizures. Am J Physiol Heart Circ Physiol 2000, 279 (3), H1346-54.
79. Sacktor, N.; Lyles, R. H.; Skolasky, R.; Kleeberger, C.; Selnes, O. A.; Miller, E. N.; Becker, J. T.; Cohen, B.; McArthur, J. C., HIVassociated neurologic disease incidence changes:: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001, 56 (2), 257-60.
80. Langford, T. D.; Letendre, S. L.; Larrea, G. J.; Masliah, E., Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol 2003, 13 (2), 195-210.
81. Avison, M. J.; Nath, A.; Greene-Avison, R.; Schmitt, F. A.; Bales, R. A.; Ethisham, A.; Greenberg, R. N.; Berger, J. R., Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J Neurovirol 2004, 10 (4), 223-32.
82. Rouquayrol, M.; Gaucher, B.; Roche, D.; Greiner, J.; Vierling, P., Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers. Pharm Res 2002, 19 (11), 1704-12.
83. Horvat, J.; Horvat, S.; Lemieux, C.; Schiller, P. W., Synthesis and biological activity of [Leu5]enkephalin derivatives containing Dglucose. Int J Pept Protein Res 1988, 31 (5), 499-507.
84. Horvat, S.; Varga, L.; Horvat, J.; Pfutzner, A.; Suhartono, H.; Rubsamenwaigmann, H., [5-Leucin]Enkephalin-Related Glycoconjugates-Structurally Novel Agents Effective against Hiv-1. Helvetica Chimica Acta 1991, 74 (5), 951-955.
85. Fine, P.; Portenoy, R., A Clinical Guide to Opioid Analgesia. McGraw Hill: 2004; p 128.
86. Smith, H. S., Opioid metabolism. Mayo Clin Proc 2009, 84 (7), 613-24.
87. Torres, J. L.; Reig, F.; Valencia, G.; Rodriguez, R. E.; Garcia-Anton, J. M., [D-Met2, Pro5] enkephalin [N1.5-beta-Dglucopyranosyl] amide: a glycosylpeptide with high antinociceptive activity. Int J Pept Protein Res 1988, 31 (5), 474-80.
88. Rodriguez, R. E.; Rodriguez, F. D.; Sacristan, M. P.; Torres, J. L.; Valencia, G.; Garcia Anton, J. M., New glycosylpeptides with high antinociceptive activity. Neurosci Lett 1989, 101 (1), 89-94.
89. Drouillat, B.; Kellam, B.; Dekany, G.; Starr, M. S.; Toth, I., Solid phase synthesis of C-terminal carbohydrate modified enkephalins. Bioorganic & Medicinal Chemistry Letters 1997, 7 (17), 2247-2250.
90. Kellam, B.; Drouillat, B.; Dekany, G.; Starr, M. S.; Toth, I., Synthesis and in vitro evaluation of lipoamino acid and carbohydrate-modified enkephalins as potential antinociceptive agents. International Journal of Pharmaceutics 1998, 161 (1), 55-64.
91. Wong, A. K.; Ross, B. P.; Chan, Y. N.; Artursson, P.; Lazorova, L.; Jones, A.; Toth, I., Determination of transport in the Caco-2 cell assay of compounds varying in lipophilicity using LC-MS: enhanced transport of Leu-enkephalin analogues. Eur J Pharm Sci 2002, 16 (3), 113-8.
92. Polt, R.; Porreca, F.; Szabo, L. Z.; Bilsky, E. J.; Davis, P.; Abbruscato, T. J.; Davis, T. P.; Harvath, R.; Yamamura, H. I.; Hruby, V. J., Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc Natl Acad Sci U S A 1994, 91 (15), 7114-8.
93. Kriss, C. T.; Lou, B. S.; Szabo, L. Z.; Mitchell, S. A.; Hruby, V. J.; Polt, R., Enkephalin-based drug design: conformational analysis of O-linked glycopeptides by NMR and molecular modeling. Tetrahedron-Asymmetry 2000, 11 (1), 9-25.
94. Erspamer, V.; Melchiorri, P.; Falconieri-Erspamer, G.; Negri, L.; Corsi, R.; Severini, C.; Barra, D.; Simmaco, M.; Kreil, G., Deltorphins: a family of naturally occurring peptides with high affinity and selectivity for delta opioid binding sites. Proc Natl Acad Sci U S A 1989, 86 (13), 5188-92.
95. Tomatis, R.; Marastoni, M.; Balboni, G.; Guerrini, R.; Capasso, A.; Sorrentino, L.; Santagada, V.; Caliendo, G.; Lazarus, L. H.; Salvadori, S., Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem 1997, 40 (18), 2948-52.
96. Negri, L.; Lattanzi, R.; Tabacco, F.; Orru, L.; Severini, C.; Scolaro, B.; Rocchi, R., Dermorphin and deltorphin glycosylated analogues: synthesis and antinociceptive activity after systemic administration. J Med Chem 1999, 42 (3), 400-4.
97. Mulder, G. J., Pharmacological effects of drug conjugates: is morphine 6-glucuronide an exception? Trends Pharmacol Sci 1992, 13 (8), 302-4.
98. Bourasset, F.; Cisternino, S.; Temsamani, J.; Scherrmann, J. M., Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier. J Neurochem 2003, 86 (6), 1564-7.
99. Arsequell, G.; Salvatella, M.; Valencia, G.; Fernandez-Mayoralas, A.; Fontanella, M.; Venturi, C.; Jimenez-Barbero, J.; Marron, E.; Rodriguez, R. E., Synthesis, conformation, and biological characterization of a sugar derivative of morphine that is a potent, long-lasting, and nontolerant antinociceptive. J Med Chem 2009, 52 (9), 2656-66.
100. Palian, M. M.; Boguslavsky, V. I.; O'Brien, D. F.; Polt, R., Glycopeptide-membrane interactions: glycosyl enkephalin analogues adopt turn conformations by NMR and CD in amphipathic media. J Am Chem Soc 2003, 125 (19), 5823-31.
101. Gynther, M.; Ropponen, J.; Laine, K.; Leppanen, J.; Haapakoski, P.; Peura, L.; Jarvinen, T.; Rautio, J., Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats. J Med Chem 2009, 52 (10), 3348-53.
102. Costantino, L.; Gandolfi, F.; Tosi, G.; Rivasi, F.; Vandelli, M. A.; Forni, F., Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J Control Release 2005, 108 (1), 84-96.
103. Tosi, G.; Costantino, L.; Rivasi, F.; Ruozi, B.; Leo, E.; Vergoni, A. V.; Tacchi, R.; Bertolini, A.; Vandelli, M. A.; Forni, F., Targeting the central nervous system: in vivo experiments with peptidederivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Release 2007, 122 (1), 1-9.
104. Vergoni, A. V.; Tosi, G.; Tacchi, R.; Vandelli, M. A.; Bertolini, A.; Costantino, L., Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomedicine 2009, 5 (4), 369-77.
105. Tosi, G.; Vergoni, A. V.; Ruozi, B.; Bondioli, L.; Badiali, L.; Rivasi, F.; Costantino, L.; Forni, F.; Vandelli, M. A., Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. J Control Release 2010, 145 (1), 49-57.
106. Alyautdin, R. N.; Petrov, V. E.; Langer, K.; Berthold, A.; Kharkevich, D. A.; Kreuter, J., Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 1997, 14 (3), 325-8.
107. DiNunzio, J. C.; Williams, 3rd R. O., CNS disorders-current treatment options and the prospects for advanced therapies. Drug Dev Ind Pharm 2008, 34 (11), 1141-67.